Követés
Peter Mullen
Peter Mullen
Research Fellow, University of St Andrews
E-mail megerősítve itt: st-andrews.ac.uk
Cím
Hivatkozott rá
Hivatkozott rá
Év
New strategies for targeting the hypoxic tumour microenvironment in breast cancer
C Ward, SP Langdon, P Mullen, AL Harris, DJ Harrison, CT Supuran, ...
Cancer treatment reviews 39 (2), 171-179, 2013
2252013
Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells
F Hochgräfe, L Zhang, SA O'Toole, BC Browne, M Pinese, A Porta Cubas, ...
Cancer research 70 (22), 9391-9401, 2010
2092010
Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab
D Faratian, A Goltsov, G Lebedeva, A Sorokin, S Moodie, P Mullen, C Kay, ...
Cancer research 69 (16), 6713-6720, 2009
1932009
Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer
K Macleod, P Mullen, J Sewell, G Rabiasz, S Lawrie, E Miller, JF Smyth, ...
Cancer research 65 (15), 6789-6800, 2005
1702005
Regulation of aromatase activity within the breast
WR Miller, P Mullen, P Sourdaine, C Watson, JM Dixon, J Telford
The Journal of steroid biochemistry and molecular biology 61 (3-6), 193-202, 1997
1351997
Novel flavonoids as anti-cancer agents: mechanisms of action and promise for their potential application in breast cancer
C Martinez-Perez, C Ward, G Cook, P Mullen, D McPhail, DJ Harrison, ...
Biochemical Society Transactions 42 (4), 1017-1023, 2014
972014
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models
C Ward, J Meehan, P Mullen, C Supuran, JM Dixon, JS Thomas, ...
Oncotarget 6 (28), 24856, 2015
892015
Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer
F McPhillips, P Mullen, BP Monia, AA Ritchie, FA Dorr, JF Smyth, ...
British journal of cancer 85 (11), 1753-1758, 2001
892001
Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines
P Mullen, A Ritchie, SP Langdon, WR Miller
International journal of cancer 67 (6), 816-820, 1996
811996
Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop
A Pandyra, PJ Mullen, M Kalkat, R Yu, JT Pong, Z Li, S Trudel, KS Lang, ...
Cancer research 74 (17), 4772-4782, 2014
792014
PARP cleavage as a means of assessing apoptosis
P Mullen
Cancer Cell Culture: Methods and Protocols, 171-181, 2004
702004
Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines
JY Winum, F Carta, C Ward, P Mullen, D Harrison, SP Langdon, A Cecchi, ...
Bioorganic & medicinal chemistry letters 22 (14), 4681-4685, 2012
632012
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling
P Mullen, DA Cameron, M Hasmann, JF Smyth, SP Langdon
Molecular cancer therapeutics 6 (1), 93-100, 2007
612007
Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies
D Faratian, AJM Zweemer, Y Nagumo, AH Sims, M Muir, M Dodds, ...
Clinical Cancer Research 17 (13), 4451-4461, 2011
602011
Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells
F McPhillips, P Mullen, KG MacLeod, JM Sewell, BP Monia, DA Cameron, ...
Carcinogenesis 27 (4), 729-739, 2006
582006
Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo
K Morgan, AJ Stewart, N Miller, P Mullen, M Muir, M Dodds, F Medda, ...
Cancer research 68 (15), 6331-6340, 2008
572008
The use of Matrigel to facilitate the establishment of human cancer cell lines as xenografts
P Mullen
Cancer Cell Culture: Methods and Protocols, 287-292, 2004
552004
Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines
KE Wilson, JMS Bartlett, EP Miller, JF Smyth, P Mullen, WR Miller, ...
British Journal of Cancer 80 (5), 685-692, 1999
551999
Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy
D Faratian, AH Sims, P Mullen, C Kay, IH Um, SP Langdon, DJ Harrison
PloS one 6 (8), e23772, 2011
532011
Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models
C Martínez-Pérez, C Ward, AK Turnbull, P Mullen, G Cook, J Meehan, ...
British Journal of Cancer 114 (8), 905-916, 2016
512016
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20